University Cancer & Blood Center’s Dr. Ashley Ray receives oncoplastic breast surgery certification
February 06, 2025 11:48 ET
|
University, Cancer and Blood Center
University Cancer & Blood Center (UCBC), based in Athens, Georgia, announces that Dr. Ashley Ray now has her certification in oncoplastic breast surgery.
Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program
February 06, 2025 08:30 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response...
Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
February 06, 2025 08:00 ET
|
Allarity Therapeutics, Inc.
Boston (February 6, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a...
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
February 06, 2025 07:00 ET
|
Immuneering Corporation
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
Nuclear Medicine Market Size to Accumulate Around USD 38.8 Billion by 2032, Growing at a 15% CAGR - SNS Insider
February 05, 2025 09:30 ET
|
SNS Insider pvt ltd
Pune, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Nuclear Medicine Market Size & Growth Analysis: According to SNS Insider, The Global Nuclear Medicine Market size was valued at USD 11.1 billion in 2023...
Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
February 05, 2025 08:00 ET
|
AIM ImmunoTech Inc.
Safety Committee approval based on positive Phase 1 safety data demonstrating the combination therapy to be generally well-tolerated with no severe treatment-related adverse events or dose-limiting...
Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025
February 05, 2025 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused...
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 03, 2025 16:05 ET
|
Immuneering Corporation
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Cancer Diagnostics Market Size is Expected to Reach USD 178.26 Billion by 2033, Growing at a CAGR of 5.91%: Straits Research
February 03, 2025 08:25 ET
|
Straits Research Private Limited - Garner Insights
New York, United States, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Cancer diagnostics is the process of identifying biomarkers, proteins, and other indicators that assist in identifying a cancerous tumor....
Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
February 03, 2025 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...